PolyPid (PYPD) News Today $2.79 -0.01 (-0.36%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$2.76 -0.02 (-0.90%) As of 05/2/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Contrasting PolyPid (NASDAQ:PYPD) and United American Healthcare (OTCMKTS:UAHC)April 30 at 2:20 AM | americanbankingnews.comPolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025April 29, 2025 | globenewswire.comPolyPid to Participate in The Citizens Life Sciences ConferenceApril 22, 2025 | globenewswire.comPolyPid management to meet with OppenheimerApril 17, 2025 | markets.businessinsider.comBarclays Reaffirms Their Hold Rating on PolyPid (PYPD)March 25, 2025 | markets.businessinsider.comPolyPid completes enrollment in SHIELD II Phase 3 trial for D-PLEX100March 12, 2025 | markets.businessinsider.comCraig-Hallum Remains a Buy on PolyPid (PYPD)March 12, 2025 | markets.businessinsider.comPolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection PreventionMarch 11, 2025 | tipranks.comPolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsMarch 11, 2025 | globenewswire.comPolyPid to Participate in the 37th Annual ROTH ConferenceMarch 3, 2025 | globenewswire.comPolyPid Ltd (PYPD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D CostsFebruary 13, 2025 | finance.yahoo.comPolyPid targets SHIELD II trial completion with top-line results in Q2 2025February 12, 2025 | msn.comPolyPid (PYPD) Gets a Buy from JMP SecuritiesFebruary 12, 2025 | markets.businessinsider.comPolyPid Ltd. (PYPD) Q4 2024 Earnings Call TranscriptFebruary 12, 2025 | seekingalpha.comPolyPid Updates: New Board Appointment and SHIELD II Trial ProgressFebruary 12, 2025 | tipranks.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial ResultsFebruary 12, 2025 | globenewswire.comCraig-Hallum Sticks to Its Buy Rating for PolyPid (PYPD)February 10, 2025 | markets.businessinsider.comPolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceJanuary 30, 2025 | globenewswire.comPolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025January 29, 2025 | globenewswire.comPolyPid initiated with a Buy at Rodman & RenshawJanuary 29, 2025 | markets.businessinsider.comRodman & Renshaw sets PolyPid stock at Buy with $13 targetJanuary 29, 2025 | msn.comPolyPid files to sell 11.23M ordinary shares for holdersJanuary 22, 2025 | markets.businessinsider.comPolyPid Regains Nasdaq Compliance with Private Placement BoostJanuary 17, 2025 | tipranks.comPolyPid (NASDAQ:PYPD) Stock Quotes, Forecast and News SummaryDecember 26, 2024 | benzinga.comPolyPid price target lowered to $11 from $14 at H.C. WainwrightDecember 26, 2024 | markets.businessinsider.comPolyPid’s SHIELD II Trial Progress and Financial Stability Justify Buy RatingDecember 25, 2024 | markets.businessinsider.comPolyPid announces DSMB recommendation to continue Phase 3 D-PLEX studyDecember 24, 2024 | markets.businessinsider.comPolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 MillionDecember 23, 2024 | globenewswire.comPolyPid’s Strategic Advancements and Clinical Progress: A Buy RecommendationDecember 16, 2024 | markets.businessinsider.comPolyPid announces research, development collaboration with ImmunoGenesisDecember 12, 2024 | markets.businessinsider.comPolyPid (PYPD) Gets a Buy from Craig-HallumDecember 12, 2024 | markets.businessinsider.comPolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer ImmunotherapyDecember 11, 2024 | globenewswire.comPolyPid Ltd.: PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-ComplianceNovember 30, 2024 | finanznachrichten.dePolyPid receives noncompliance notification from NasdaqNovember 29, 2024 | markets.businessinsider.comPolyPid Faces Nasdaq Non-Compliance ChallengeNovember 29, 2024 | tipranks.comPolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-ComplianceNovember 29, 2024 | globenewswire.comPolyPid (PYPD) Gets a Hold from BarclaysNovember 19, 2024 | markets.businessinsider.comPositive Indicators and Financial Stability Support Roy Buchanan’s Optimistic Outlook on PolyPid’s StockNovember 16, 2024 | markets.businessinsider.comPolyPid Reports Q3 Results Amid SHIELD II Trial ProgressNovember 15, 2024 | markets.businessinsider.comPolyPid Announces SHIELD II Trial Progress and FinancialsNovember 14, 2024 | markets.businessinsider.comPolyPid Ltd. (PYPD) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comPolyPid (PYPD) Receives a Buy from Craig-HallumNovember 12, 2024 | markets.businessinsider.comPolyPid Announces $8.25 Million Share Sale PlanNovember 9, 2024 | markets.businessinsider.comPolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select ConferenceNovember 7, 2024 | globenewswire.comCraig-Hallum bullish on PolyPid, initiates with a BuyNovember 6, 2024 | markets.businessinsider.comCraig-Hallum Initiates Coverage of PolyPid (PYPD) with Buy RecommendationNovember 6, 2024 | msn.comPolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024October 30, 2024 | globenewswire.comRosalind Advisors, Inc. Reduces Stake in PolyPid LtdOctober 24, 2024 | finance.yahoo.comPolyPid announces publication in IJS on Phase 3 SHIELD I trial of D-PLEX100October 22, 2024 | markets.businessinsider.comPolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal SurgeryOctober 21, 2024 | globenewswire.com Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address PYPD Media Mentions By Week PYPD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PYPD News Sentiment▼-0.030.58▲Average Medical News Sentiment PYPD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PYPD Articles This Week▼21▲PYPD Articles Average Week Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Orchestra BioMed News Microbot Medical News Sharps Technology News iCAD News Edap Tms News Milestone Scientific News FONAR News Sensus Healthcare News InspireMD News Inovio Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PYPD) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
